Effects of telemedicine interventions on essential hypertension: a protocol for a systematic review and meta-analysis. Issue 9 (29th September 2022)

• Record Type: Journal Article
• Authors: Zhu, Ling; Li, Dongze; Jiang, Xiao-Lian; Jia, Yu; Liu, Yi; Li, Fanghui; Chen, Xiaoli; Lin, Tao; Diao, Dongmei; Gao, Yongli
• Is Part Of: BMJ open. Volume 12:Issue 9(2022)
• Publication Date: 2022-09-29
• Subjects: Telemedicine -- Information technology -- Information management -- Hypertension; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2021-060376
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Essential hypertension is a major preventable risk factor for early cardiovascular disease, premature death and disability. It has been reported that telemedicine interventions can provide an innovative solution to essential hypertension to overcome the barriers that exist in traditional treatment or control. Nevertheless, this subject has not been thoroughly investigated. The goal of this study is to systematically evaluate and describe the impact of telemedicine interventions on essential hypertension. Methods and analysis: To find relevant research, we will conduct a systematic literature search of three databases (PubMed, Embase and Cochrane Library), with no language limitations, in addition to researching grey literature. Two reviewers will extract the data individually, and any disagreements will be resolved by discussion or by a third reviewer. The randomised controlled trials will be chosen based on predetermined inclusion criteria. Primary outcomes will include systolic blood pressure and diastolic blood pressure after the telemedicine intervention. Secondary outcomes will include medication adherence (eg, the Morisky Medication Adherence Questionnaire), quality of life (eg, the MOS item scale of the Health Survey Short Form 36 questionnaire), blood pressure control rate and adverse events (eg, stroke, chronic renal failure, aortic dissection, myocardial infarction and heart failure). The quality of the included studies will be assessed using the Cochrane risk-of-bias method. The data will be analysed using RevMan V.5.3.5 software and STATA V.16.0 software. If heterogeneity testing reveals little or no statistical heterogeneity, a fixed effect model will be used for data synthesis; otherwise, a random effect model would be employed. We will synthesise the available evidence to perform a high-quality meta-analysis. Ethics and dissemination: This project does not require ethical approval because it will be conducted using publicly available documents. The review's findings will be published in peer-reviewed journals and publications. PROSPERO registration number: CRD42021293539.